Tandem inks distribution deal in Scandinavia for insulin pumps

Tandem Diabetes Care (NSDQ:TNDM) has inked a distribution agreement with Rubin Medical to commercialize the medical device company’s t:slim X2 insulin pump, insulin cartridges and t:lock infusion sets in Sweden, Norway and Denmark.

According to the terms of the deal, Rubin Medical is slated to perform all sales, marketing and customer training for Tandem’s devices.

“This represents the first pump distribution agreement for Tandem Diabetes Care outside of the United States and is a significant step forward for our international commercialization strategy,” Tandem’s president & CEO, Kim Blickenstaff, said in prepared remarks.

“Rubin Medical’s proven success with insulin pumps in Sweden, Norway and Denmark, and their demonstrated support of patients and clinicians impacted by diabetes, make them an ideal distributor for us in these countries,” he added.

“We are thrilled to be able to bring the first touchscreen insulin pump to our diabetes communities in Scandinavia,” Karl-Johan Öhman, CEO & managing director of Rubin Medical, said. “We believe the t:slim X2 Pump will be well received in these countries. We’re very happy to add this product to our portfolio and to be one of the first markets outside of the United States to offer this exciting option to patients and clinics.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Inside Hologic's evolving definition of women's healthcare Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business. At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it! REGISTER NOW Use code WOMENSHEALTH to save an additional 10%.